Mifepristone as a non-emergency contraceptive among women of reproductive age: a protocol for systematic review and meta-analysis

Mifepristone as a non-emergency contraceptive among women of reproductive age: a protocol for systematic review and meta-analysis

Background Mifepristone is a selective progesterone receptor modulator with decades of data demonstrating its potential as a highly effective emergency as well as non-emergency contraceptive. Despite considerable evidence pointing to the potential effectiveness of mifepristone as a non-emergency con...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kristina Gemzell-Danielsson, Rebecca Gomperts, Lisa Haddad, Miriam Nkangu, Caroline Frisendahl, Chelsea Polis, Tracy Chen, Evan Sterling, Marlena Plagianos
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-12-01
Series:	BMJ Open
Online Access:	https://bmjopen.bmj.com/content/14/12/e090402.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Non‐daily contraception: Reinforcing the choice of users and addressing unmet needs of reproductive health
by: Helena Kopp Kallner, et al.
Published: (2025-02-01)

Contraceptive uptake and compliance after structured contraceptive counseling ‐ secondary outcomes of the LOWE trial
by: Isabella Bizjak, et al.
Published: (2024-05-01)

One‐year follow up of contraceptive use and pregnancy rates after early medical abortion: Secondary outcomes from a randomized controlled trial of immediate post‐abortion placement of intrauterine devices
by: Sara Hogmark, et al.
Published: (2023-12-01)

Effects of structured contraceptive counseling in young women: Secondary analyses of a cluster randomized controlled trial (the LOWE trial)
by: Karin Emtell Iwarsson, et al.
Published: (2024-11-01)

Healthcare providers' perceptions on post abortion intrauterine contraception: A qualitative study in central Uganda.
by: Herbert Kayiga, et al.
Published: (2024-01-01)

Contraceptive use among women seeking an early induced abortion in Sweden
by: Jenny Niemeyer Hultstrand, et al.
Published: (2023-11-01)

Two decades of research capacity strengthening and reciprocal learning on sexual and reproductive health in East Africa – a point of (no) return
by: Caroline Frisendahl, et al.
Published: (2024-12-01)

Perceptions of women and their partners on postabortion intrauterine contraception: A qualitative study in central Uganda.
by: Herbert Kayiga, et al.
Published: (2025-01-01)

Medicamentous abortion with mifepristone and misoprostol in Serbia and Montenegro
by: Stojnić Jelena, et al.
Published: (2006-01-01)

The Origins and Proliferation of Unfounded Comparisons Regarding the Safety of Mifepristone
by: Cameron Louttit
Published: (2025-05-01)

Reproductive changes among women in their 40s: A cross‐sectional study
by: Ingela Lindh, et al.
Published: (2022-02-01)

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing’s Syndrome
by: Andreas G. Moraitis, et al.
Published: (2016-01-01)

Antitumor effect of mifepristone on human endometrial stromal cell line
by: Luković Jovan, et al.
Published: (2021-01-01)

Treatment of a Woman with Inoperable Meningioma Using Mifepristone for 26 Years
by: Maria das Dores Medina-Lopes, et al.
Published: (2020-01-01)

miR-193b-5p and miR-374b-5p Are Aberrantly Expressed in Endometriosis and Suppress Endometrial Cell Migration In Vitro
by: Caroline Frisendahl, et al.
Published: (2024-11-01)

CONTRACEPTION IN THE LATE REPRODUCTIVE AND PRE-CLIMACTERIC PERIODS
by: I. O. Makarov, et al.
Published: (2016-08-01)

Effectiveness and Safety of Medical Abortion with Mifepristone and Sublingual Misoprostol up to 63 Days of Gestation
by: Prakasit Saengbanyang, et al.
Published: (2024-09-01)

Mifepristone-related foetal cardiac adverse events: findings from the postmarketing safety reports
by: Ran Liu, et al.
Published: (2025-12-01)

Mifepristone and rapamycin have non-additive benefits for life span in mated female Drosophila
by: Gary N. Landis, et al.
Published: (2024-12-01)

RuX: A Novel, Flexible, and Sensitive Mifepristone-Induced Transcriptional Regulation System
by: Anne Meinzinger, et al.
Published: (2023-01-01)

Therapeutic effect of mifepristone combined with misoprostol in early missed miscarriage and prediction of incomplete abortion
by: Bai Xue, et al.
Published: (2025-04-01)

Effectiveness and acceptability of home use of misoprostol for medical abortion up to 10 weeks of pregnancy
by: Volodymyr Podolskyi, et al.
Published: (2023-05-01)

Safety and Efficacy of Oral Mifepristone for Cervical Ripening in Single Live Intrauterine Term Unscarred Pregnancies
by: Sarika Rawat, et al.
Published: (2025-05-01)

The potential regulatory role of non-coding RNAs in mifepristone-induced masculinization in Takifugu rubripes gonads
by: Rui Gao, et al.
Published: (2025-05-01)

Is self-assessment of medical abortion using a low-sensitivity pregnancy test combined with a checklist and phone text messages feasible in South African primary healthcare settings? A randomized trial.
by: Deborah Constant, et al.
Published: (2017-01-01)

Emergency contraceptive. One more contraceptive option.
by: Ana Teresa Fernández Vidal, et al.
Published: (2003-07-01)

Effects of Mifepristone on Nonalcoholic Fatty Liver Disease in a Patient with a Cortisol-Secreting Adrenal Adenoma
by: Enzo Ragucci, et al.
Published: (2017-01-01)

Spatial Disparities in Mifepristone Use for Early Miscarriage and Induced Abortion Among Obstetrician–Gynecologists Practicing in Massachusetts
by: Emily Newton-Hoe, et al.
Published: (2024-04-01)

Reproductive outcomes of patients with unfulfilled postpartum permanent contraception requests
by: Grace A. Trompeter, et al.
Published: (2025-07-01)

Contraceptive usage in women requesting emergency contraception in Swaziland
by: S. A. Sonubi, et al.
Published: (2015-05-01)

Concerns About Contraception and Future Fertility: Prevalence Among Young Individuals and Its Impact on Contraceptive Use and Reproductive Health
by: Naheed Akhtar, et al.
Published: (2025-07-01)

A randomized comparison of three early medical abortion regimes: Mifepristone and misoprostol, misoprostol alone and methotrexate and misoprostol
by: Renuka Brijwal, et al.
Published: (2025-07-01)

Factors related to successful medication management with mifepristone and misoprostol in missed miscarriage: a retrospective case-control study
by: Huiyuan Wang, et al.
Published: (2025-05-01)

Impact of Hormonal Contraceptives on Iron (Fe) Status in Females of Reproductive Age
by: Mariana Bolinaga Sanz, et al.
Published: (2025-05-01)

Reproductive milestones and oral contraceptive timing predict late-life mortality
by: Saul Justin Newman, et al.
Published: (2025-05-01)

Intravaginal hormonal contraception for women of reproductive age with excessive body mass
by: I. B. Gridina
Published: (2015-12-01)

Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study.
by: Miguel Debono, et al.
Published: (2013-01-01)

Hysteroscopic Myomectomy for Type 2 Submucosal Myoma Pretreated by HIFU and Mifepristone Treatment: A Case Report and Literature Review
by: Li J, et al.
Published: (2025-08-01)

Assessing the impact of contraceptive use on reproductive cancer risk among women of reproductive age—a systematic review
by: Shayesteh Jahanfar, et al.
Published: (2024-11-01)

A comparison of acceptability of contraceptive vaginal rings, pills, and injectables among cisgender women in Kenya and Zimbabwe: protocol for a mixed-methods study [version 1; peer review: awaiting peer review]
by: Chelsea B. Polis, et al.
Published: (2025-03-01)